Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$418.84M+166.82%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Martha Goldberg Aronson
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 7,500
- Beta
- 0.49
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 4.22
Financials
Revenue
$418.84M+166.8%Net Income
$38.80M+3888.0%EBITDA
$97.40M+553.4%Free Cash Flow
$51.09M+917.8%EPS (diluted)
$0.65+3150.0%Shares Outstanding (diluted)
60.01M+33.3%Operating Expenses
$154.62MCash & Debt
$448.70MRevenue by Segment (annual)
$1.52BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.51B | $128.49M | $2.17 |
| 2024 | $1.36B | $120.36M | $2.07 |
| 2023 | $1.26B | $94.41M | $1.64 |
| 2022 | $1.15B | $74.52M | $1.31 |
| 2021 | $1.07B | $48.45M | $0.86 |
| 2020 | $963.88M | $-9.84M | $-0.18 |
| 2019 | $994.85M | $5.45M | $0.10 |
| 2018 | $882.75M | $42.02M | $0.80 |
| 2017 | $727.85M | $27.52M | $0.56 |
| 2016 | $603.84M | $20.12M | $0.45 |
| 2015 | $542.15M | $23.80M | $0.54 |
| 2014 | $509.69M | $22.97M | $0.53 |
| 2013 | $449.05M | $16.57M | $0.39 |
| 2012 | $394.29M | $19.71M | $0.47 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MMSI's reported EPS growth of 12.5% a year over 13 years.
- EPS in 5 years
- $3.91
- Implied price
- $160.47
- Return from $85.37
- 13.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $79.78 — -6.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 29 | 35 | 41 | 47 | 53 |
|---|---|---|---|---|---|
| 2.5% | -3.5% | 0.1% | 3.4% | 6.2% | 8.8% |
| 7.5% | 1.2% | 5.0% | 8.4% | 11.4% | 14.1% |
| 12.5% | 5.9% | 9.9% | 13.5% | 16.6% | 19.4% |
| 17.5% | 10.6% | 14.8% | 18.5% | 21.8% | 24.7% |
| 22.5% | 15.3% | 19.7% | 23.5% | 27.0% | 30.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-70.59%Social Signal Score
Mentions (13)
- Newsdefenseworld.net·12d ago·Neutral
Financial Survey: Merit Medical Systems (NASDAQ:MMSI) vs. Bausch + Lomb (NYSE:BLCO) Merit Medical Systems (NASDAQ: MMSI - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Institutional and Insider Ownership 99.7%
View source ↗ - News (RSS)financialpost·28d ago·Negative
ICBA and Global eTraining Launch Construction Technology Training Initiative to Upskill Canadian Contractors ICBA deploys an on-demand technical training initiative, establishing an industry-leading construction technology training platform for ICBA and Merit Canada members SURREY, British Columbia, Sept. 07, 2026 (GLOBE NEWSWIRE) — The Independent Contractors and Businesses Association (ICBA) today announced a major construction technology training initiative in collaboration with Global eTrain
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Merit Medical to Participate in Upcoming Investors Conferences in September SOUTH JORDAN, Utah, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management is scheduled to participate in the following upcoming investor conferences:
View source ↗ - Newszacks.com·33d ago·Neutral
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.
View source ↗ - News (RSS)zerohedge·36d ago·Neutral
No Whites Allowed, Britain's MI5 Tells Applicants No Whites Allowed, Britain's MI5 Tells Applicants Authored by Steve Watson via Modernity News, Britain's domestic intelligence service is once again telling White university students they are not wanted. For the 2027 Summer Intelligence Internship, MI5 has confined applications to people from a "black, Asian, mixed heritage or ethnic minority background" who also come from a "socially or economically disadvantaged background." White British candi
View source ↗ - Newszacks.com·42d ago·Positive
Should You Buy MMSI as Growth Improves but Valuation Stays Elevated? Merit Medical's growth case is strengthening as launches, acquisitions and therapeutic products broaden its mix, but its premium valuation raises the execution bar.
View source ↗ - Newszacks.com·42d ago·Positive
Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves? Merit Medical's 22.2% monthly rally gains support from stronger Q2 growth and a raised 2026 outlook, but valuation and tariff risks remain.
View source ↗ - Newszacks.com·46d ago·Positive
Here's Why Merit Medical (MMSI) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - News (RSS)zerohedge·49d ago·Negative
Deep Capture: The Administrative State's Intellectual Origins Deep Capture: The Administrative State's Intellectual Origins Authored by Sofia Karstens via Brownstone Institute, Woodrow Wilson holds a distinction no other American president has: he earned a Ph.D., completing his doctorate in political science and history at Johns Hopkins University in 1886. That same year, he wrote an essay called "The Study of Administration," later published in the inaugural volume of Political Science Quarterl
View source ↗ - Newsmarketbeat.com·52d ago·Positive
Merit Medical Eyes Next Growth Plan as Margins, Portfolio Review Take Center Stage Merit Medical Systems NASDAQ: MMSI is focused on completing the objectives of its current long-range plan while developing its next strategic framework, Chief Financial Officer and Treasurer Raul Parra said during a Canaccord investor event.
View source ↗ - Newsmarketbeat.com·52d ago·Positive
Merit Medical Systems Eyes New Long-Range Plan as Growth, Margins Gain Momentum Merit Medical Systems NASDAQ: MMSI is preparing its next long-range plan as the medical-device company works through a leadership transition, updates its reporting structure and seeks to build on recent revenue and margin momentum.
View source ↗ - News (RSS)seekingalpha·54d ago·Positive
Merit Medical Systems, Inc. (MMSI) Presents at Bank of America SMID Cap Virtual Conference Transcript
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Merit Medical Systems, Inc. (MMSI) Presents at Bank of America SMID Cap Virtual Conference Transcript Merit Medical Systems, Inc. (MMSI) Presents at Bank of America SMID Cap Virtual Conference Transcript
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $1.04 per share
Typical surprise +13.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$1.19 vs $0.96beat
- Thu, Apr 30$0.94 vs $0.84beat
- Tue, Feb 24$1.04 vs $0.96beat
- Thu, Oct 30$0.92 vs $0.82beat
- Wed, Jul 30$1.01 vs $0.86beat
- Thu, Apr 24$0.86 vs $0.75beat
Estimates and results for MMSI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MMSI officers and directors.
- Bought
- $573k
- Sold
- $17.5m
5 trades
20 trades
- Peterson Neil W.sold
- Peterson Neil W.sold
- Smith Christian Adambought
- Ward Lynne N.sold
- Lloyd Brian G.bought
- Aronson Martha Goldbergbought
- Parra Raul Jr.bought
- Voigt Michel J.bought
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (27d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.